Literature DB >> 8369127

Therapeutic use of granulocyte-macrophage colony-stimulating factor (GM-CSF). A review of recent experience.

R T Costello1.   

Abstract

Recombinant cytokines are now available for clinical use. Several colony-stimulating factors (CFS) have been identified which induce activation, proliferation and maturation of myeloid lineage cells. Recent therapeutic trials with granulocyte-macrophage colony-stimulating factors (GM-CSF) in association with chemotherapy, bone marrow transplantation and leukemia treatment are reviewed. GM-CSF as primary treatment for myelodysplasia and other types of bone marrow failure is also of interest. Colony-stimulating factor therapy in AIDS may be useful in order to reduce myelodepression caused by antiviral treatment and chemotherapy for associated malignancies like Kaposi's sarcoma. However, the effect of neutrophil count increase on infection is far from clear, and the real benefit of GM-CSF in cancer therapy has yet to be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8369127     DOI: 10.3109/02841869309093617

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

1.  Combined effect of protein fusion and signal sequence greatly enhances the production of recombinant human GM-CSF in Escherichia coli.

Authors:  Palash Bhattacharya; Gaurav Pandey; Poonam Srivastava; Krishna Jyoti Mukherjee
Journal:  Mol Biotechnol       Date:  2005-06       Impact factor: 2.695

2.  Expression of recombinant human granulocyte macrophage-colony stimulating factor (hGM-CSF) in mouse urine.

Authors:  Z Y Ryoo; M O Kim; K E Kim; Y Y Bahk; J W Lee; S H Park; J H Kim; S J Byun; H Y Hwang; J Youn; T Y Kim
Journal:  Transgenic Res       Date:  2001-06       Impact factor: 2.788

3.  Bovine alpha s1-casein gene sequences direct high level expression of human granulocyte-macrophage colony-stimulating factor in the milk of transgenic mice.

Authors:  M Uusi-Oukari; J M Hyttinen; V P Korhonen; A Västi; L Alhonen; O A Jänne; J Jänne
Journal:  Transgenic Res       Date:  1997-01       Impact factor: 2.788

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.